

CLAIMS

1. An anti-tumor agent comprising one or more tubulin polymerization-inhibitory active substance having anti-tumor activity and one or more anti-inflammatory active substance.

5           2. The anti-tumor agent according to Claim 1, wherein the tubulin polymerization-inhibitory active substance having anti-tumor activity is selected from the group consisting of combretastatines and derivatives thereof, vinca alkaloids and derivatives thereof, colchicinoids and derivatives thereof, dolastatins and derivatives thereof, podophyllotoxins and derivatives thereof, steganacins and derivatives thereof, amphethiniles and derivatives thereof, flavonoids and derivatives thereof, rhizoxins and derivatives thereof, curacins A and derivatives thereof, epothilones A and derivatives thereof, epothilones B and derivatives thereof, welwistatins and derivatives thereof, phenstatins and derivatives thereof, 2-  
10       strylquinazoline-4(3H)-ones and derivatives thereof, stilbenes and derivatives thereof, 2-aryl-1,8-naphthyridin-4(1H)-ones and derivatives thereof, 5,6-dihydroindolo(2,1-a) isoquinolines and derivatives thereof, 2,3-benzo(b)thiophenes and derivatives thereof, 2,3-substituted benzo(b)furans and derivatives thereof, 2,3-substituted indoles and derivatives thereof, and 2-methoxyestradiol.

3. The anti-tumor agent according to Claim 1, wherein the anti-inflammatory active substance is an anti-inflammatory active steroid substance.

20           4. The anti-tumor agent according to Claim 1, wherein the anti-inflammatory active substance is selected from the group consisting of Dexamethasone, prednisolone, methyl prednisolone, betamethasone, triamcinolone, paramethasone, beclomethasone, fluocinolone acetone, cortisol, and derivatives thereof.

5. The anti-tumor agent according to Claim 4, wherein the Dexamethasone and  
25       derivatives thereof are selected from the group consisting of Dexamethasone, an ester of

Dexamethasone, and a salt of Dexamethasone.

6. The anti-tumor agent according to Claim 1, wherein the anti-inflammatory active substance is selected from the group consisting of anti-inflammatory active steroid substances and analogous compounds thereof, anti-inflammatory active non-steroid substances and  
5 analogous compounds thereof, and anti-inflammatory or immuno-suppressive active substances.

7. The anti-tumor agent according to Claim 6, wherein the anti-inflammatory active substance is an anti-inflammatory active steroid substance.

8. The anti-tumor agent according to Claim 6, wherein the anti-inflammatory active  
10 substance is selected from the group consisting of Dexamethasone, prednisolone, methyl prednisolone, betamethasone, triamcinolone, paramethasone, beclomethasone, fluocinolone acetonide, cortisol, and derivatives thereof.

9. The anti-tumor agent according to Claim 8, wherein the Dexamethasone and derivatives thereof are selected from the group consisting of Dexamethasone, an ester of  
15 Dexamethasone, and a salt of Dexamethasone.

10. The anti-tumor agent according to Claim 1, wherein the tubulin polymerization-inhibitory active substance is selected from the group consisting of combretastines and derivatives thereof and stilbenes and derivatives thereof, and the anti-inflammatory active substance is selected from the group consisting of Dexamethasone and derivatives thereof.

20 11. The anti-tumor agent according to Claim 1, wherein the tubulin polymerization-inhibitory active substance is (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide or salt thereof.

12. The anti-tumor agent according to Claim 1, wherein the tubulin polymerization-inhibitory active substance is in the form of an anti-tumor pharmaceutical preparation and the  
25 anti-inflammatory active substance is in the form of an anti-inflammatory agent.

13. The anti-tumor agent according to Claim 12, wherein the anti-tumor pharmaceutical preparation and the anti-inflammatory agent are separately administered.

14. The anti-tumor agent according to Claim 1, wherein the tubulin polymerization-inhibitory active substance having anti-tumor activity is present in a unit dosage form at a  
5 quantity ranging from 0.1-10000mg.

15. The anti-tumor agent according to Claim 1, wherein the anti-inflammatory active substance is present in a unit dosage form at a quantity ranging from 0.1-10000mg

16. A method for treatment of tumors, which comprises administering to a subject in need thereof a composition comprising an effective amount of one or more tubulin  
10 polymerization-inhibitory active substance having anti-tumor activity and an effective amount of one or more an anti-inflammatory active substance.

17. The method according to Claim 16, wherein said subject in need thereof is a human.

18. The method according to Claim 16, wherein said effective amount of said tubulin  
15 polymerization-inhibitory active substance having anti-tumor activity ranges from 0.1-10000mg per day.

19. The method according to Claim 16, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.

20. The method according to Claim 16, wherein the tubulin polymerization-inhibitory  
20 active substance having anti-tumor activity is selected from the group consisting of combretastatines and derivatives thereof, vinca alkaloids and derivatives thereof, colchicinoids and derivatives thereof, dolastatins and derivatives thereof, podophyllotoxins and derivatives thereof, steganacins and derivatives thereof, amphethiniles and derivatives thereof, flavonoids and derivatives thereof, rhizoxins and derivatives thereof, curacins A and  
25 derivatives thereof, epothilones A and derivatives thereof, epothilones B and derivatives

thereof, welwistatins and derivatives thereof, phenstatins and derivatives thereof, 2-  
strylquinazoline-4(3H)-ones and derivatives thereof, stilbenes and derivatives thereof, 2-aryl-  
1,8-naphthyridin-4(1H)-ones and derivatives thereof, 5,6-dihydroindolo(2,1-a) isoquinolines  
and derivatives thereof, 2,3-benzo(b)thiophenes and derivatives thereof, 2,3-substituted  
5 benzo(b)furans and derivatives thereof, 2,3-substituted indoles and derivatives thereof, and 2-  
methoxyestradiol.

21. The method according to Claim 16, wherein the anti-inflammatory active  
substance is selected from the group consisting of Dexamethasone, prednisolone, methyl  
prednisolone, betamethasone, triamcinolone, paramethasone, beclomethasone, fluocinolone  
10 acetone, cortisol, and derivatives thereof.

22. A method for treatment of tumors, comprising administering to a subject in need  
thereof (a) a composition comprising an effective amount of one or more tubulin  
polymerization-inhibitory active substance having anti-tumor activity and (b) a composition  
comprising an effective amount of one or more anti-inflammatory active substance.

15 23. The method according to Claim 22, wherein (a) and (b) are administered  
simultaneously or sequentially.

24. The method according to Claim 22, wherein said subject in need thereof is a  
human.

25 25. The method according to Claim 22, wherein said effective amount of said tubulin  
polymerization-inhibitory active substance having anti-tumor activity ranges from 0.1-  
10000mg per day.

26. The method according to Claim 22, wherein said effective amount of said anti-  
inflammatory active substance ranges from 0.1-10000mg per day.

27. The method according to Claim 22, wherein the tubulin polymerization-inhibitory  
25 active substance having anti-tumor activity is selected from the group consisting of

combretastatines and derivatives thereof, vinca alkaloids and derivatives thereof, colchicinoids and derivatives thereof, dolastatins and derivatives thereof, podophyllotoxins and derivatives thereof, steganacins and derivatives thereof, amphetiniles and derivatives thereof, flavonoids and derivatives thereof, rhizoxins and derivatives thereof, curacins A and derivatives thereof, epothilones A and derivatives thereof, epothilones B and derivatives thereof, welwistatins and derivatives thereof, phenstatins and derivatives thereof, 2-strylquinazoline-4(3H)-ones and derivatives thereof, stilbenes and derivatives thereof, 2-aryl-1,8-naphthyridin-4(1H)-ones and derivatives thereof, 5,6-dihydroindolo(2,1-a) isoquinolines and derivatives thereof, 2,3-benzo(b)thiophenes and derivatives thereof, 2,3-substituted benzo(b)furans and derivatives thereof, 2,3-substituted indoles and derivatives thereof, and 2-methoxyestradiol.

28. The method according to Claim 22, wherein the anti-inflammatory active substance is selected from the group consisting of Dexamethasone, prednisolone, methyl prednisolone, betamethasone, triamcinolone, paramethasone, beclomethasone, fluocinolone acetoneide, cortisol, and derivatives thereof.

29. A composition comprising (a) (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide, an ester thereof, or an salt thereof, and (b) dexamethasone, an ester thereof, or an salt thereof.